<DOC>
	<DOC>NCT01403116</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.</brief_summary>
	<brief_title>Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Eunuchism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Serum testosterone of less than or equal to 300 ng/dL on two occasions within one week (may wash out from previous oral, topical or buccal testosterone therapy) Significant intercurrent disease of any type, in particular liver, kidney, uncontrolled or poorly controlled heart disease, or psychiatric illness Recent history of stroke, not including transient ischemic attack Untreated, sever obstructive sleep apnea. Hematocrit &lt;35% or &gt;48 Serum transaminases &gt;2 times upper limit of normal, serum bilirubin &gt; 2.0 mg/dL and serum creatinine &gt; 2.0 mgk/dL BMI &gt; or equal to 36 Stable doses of lipidlowering medication for less than 3 months Stable doses of oral medication for diabetes for less than 2 months Abnormal prostate DRE [palpable nodule(s)], elevated PSA (&gt;4 ng/mL), IPSS score &gt; or equal to 19 points. History of breast cancer Use of dietary supplement saw palmetto or phytoestrogens and use of any dietary supplements that may increase serum testosterone within previous 4 weeks Known malabsorption syndrome and/or current treatment with oral lipase inhibitors History of abuse of alcohol or any drug substance within the previous 2 years Current use of antiandrogens, estrogens, oral CYP3A4 inducers or inhibitors, or longacting opioid analgesics Receipt of any drug as part of a research study within 30 days of initial dose administration in this study. Blood donation within the 12 week period before the initial study dose.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>testosterone</keyword>
	<keyword>male hypogonadism</keyword>
	<keyword>low testosterone</keyword>
</DOC>